Literature DB >> 2390489

Cyclosporin A and verapamil have different effects on energy metabolism in multidrug-resistant tumour cells.

H J Broxterman1, H M Pinedo, G J Schuurhuis, J Lankelma.   

Abstract

Cyclosporin A (Sandimmune) rapidly induced an increase in daunorubicin accumulation in multidrug-resistant human ovarian carcinoma cells (2780AD) and was more potent than verapamil. Steady-state 3H-cyclosporin A accumulation at 37 degrees C in 2780AD cells was 60-70% of that in the sensitive A2780 cells. A rapid increase of ATP consumption and lactate production was induced in 2780AD cells by verapamil, but not by cyclosporin A. These results suggest that the interactions of cyclosporin A and verapamil with P-glycoprotein, which leads to inhibition of drug transport, have a different mechanistic basis.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2390489      PMCID： PMC1971735          DOI： 10.1038/bjc.1990.234

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  34 in total

1.  Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukemia.

Authors:  M Inaba; R K Johnson
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

2.  Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein.

Authors:  B M Foxwell; A Mackie; V Ling; B Ryffel
Journal:  Mol Pharmacol       Date:  1989-10       Impact factor: 4.436

Review 3.  Membrane transport of anthracyclines.

Authors:  T Skovsgaard; N I Nissen
Journal:  Pharmacol Ther       Date:  1982       Impact factor: 12.310

4.  Enhancement of etoposide-induced cytotoxicity by cyclosporin A.

Authors:  R Osieka; S Seeber; R Pannenbäcker; D Soll; P Glatte; C G Schmidt
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Reversal of adriamycin resistance by verapamil in human ovarian cancer.

Authors:  A M Rogan; T C Hamilton; R C Young; R W Klecker; R F Ozols
Journal:  Science       Date:  1984-06-01       Impact factor: 47.728

6.  Daunomycin accumulation in resistant tumor cells as a screening model for resistance modifying drugs: role of protein binding.

Authors:  H J Broxterman; C M Kuiper; G J Schuurhuis; J J van der Hoeven; H M Pinedo; J Lankelma
Journal:  Cancer Lett       Date:  1987-04       Impact factor: 8.679

7.  Purine modulation of thymidine activity in L1210 leukemia cells in vitro.

Authors:  A Leyva; H Appel; H M Pinedo
Journal:  Leuk Res       Date:  1982       Impact factor: 3.156

8.  Cyclosporin partitions into phospholipid vesicles and disrupts membrane architecture.

Authors:  M Haynes; L Fuller; D H Haynes; J Miller
Journal:  Immunol Lett       Date:  1985       Impact factor: 3.685

Review 9.  Calcium channel blocker enhancement of anticancer drug cytotoxicity--a review.

Authors:  L Helson
Journal:  Cancer Drug Deliv       Date:  1984

10.  Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma.

Authors:  L M Slater; P Sweet; M Stupecky; M W Wetzel; S Gupta
Journal:  Br J Cancer       Date:  1986-08       Impact factor: 7.640
View more
  11 in total

1.  Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro.

Authors:  K Osann; P Sweet; L M Slater
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?

Authors:  Francisco S Chung; Jayson S Santiago; Miguel Francisco M De Jesus; Camille V Trinidad; Melvin Floyd E See
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

3.  Influence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on (18)F-2-Fluoro-2-Deoxy-D-glucose ( (18)F-FDG) Brain Kinetics.

Authors:  Nicolas Tournier; Wadad Saba; Sébastien Goutal; Philippe Gervais; Héric Valette; Jean-Michel Scherrmann; Michel Bottlaender; Salvatore Cisternino
Journal:  AAPS J       Date:  2015-02-26       Impact factor: 4.009

4.  In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance.

Authors:  Teréz Márián; Gábor Szabó; Katalin Goda; Henrietta Nagy; Nóra Szincsák; István Juhász; László Galuska; László Balkay; Pál Mikecz; Lajos Trón; Zoltán Krasznai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-27       Impact factor: 9.236

Review 5.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 6.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

7.  Secondary combined resistance to the multidrug-resistance-reversing activity of cyclosporin A in the cell line F4-6RADR-CsA.

Authors:  M Dietel; I Herzig; A Reymann; I Brandt; B Schaefer; A Bunge; H J Heidebrecht; A Seidel
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

8.  P-glycoprotein Blockers Augment the Effect of Mitomycin C on Human Tenon's Fibroblasts.

Authors:  Andrew J R White; Elizabeth Kelly; Paul R Healey; Jonathan G Crowston; Paul Mitchell; Hans Zoellner
Journal:  Transl Vis Sci Technol       Date:  2013-06-28       Impact factor: 3.283

9.  Functional evidence of multidrug resistance transporters (MDR) in rodent olfactory epithelium.

Authors:  Adrien Molinas; Gilles Sicard; Ingrid Jakob
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

10.  Cortisol is transported by the multidrug resistance gene product P-glycoprotein.

Authors:  C K van Kalken; H J Broxterman; H M Pinedo; N Feller; H Dekker; J Lankelma; G Giaccone
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.